Neurological disorders stem cell therapies - TCA Cellular Therapy

Drug Profile

Neurological disorders stem cell therapies - TCA Cellular Therapy

Latest Information Update: 29 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TCA Cellular Therapy
  • Class Antineoplastics; Cardiovascular therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Spinal cord injuries

Most Recent Events

  • 29 Jun 2015 Discontinued - Phase-I for Amyotrophic lateral sclerosis in USA (Intrathecal)
  • 29 Jun 2015 Discontinued - Phase-I for Spinal cord injuries in USA (Intrathecal)
  • 01 May 2014 Suspended - Phase-I for Amyotrophic lateral sclerosis in USA (Intrathecal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top